FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1844-1845 December 12, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Attal, M. PubMed Citation

To the Editor: Attal et al. (July 11 issue)¹ state that their trial "demonstrates that high-dose therapy improves both event-free and overall survival" in patients with multiple myeloma, but that conclusion is not supported by their data. Although the unadjusted difference in overall survival between the patients receiving high-dose chemotherapy (some of whom also underwent autologous bone marrow transplantation) and those receiving conventional chemotherapy was associated with a P value of 0.03, multivariate analysis revealed that "overall survival was related only to the level of beta₂-microglobulin (P<0.001)." This discrepancy between unadjusted and adjusted results indicates that there was substantial . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Attal, M., Moreau, P., Avet-Loiseau, H., Harousseau, J.-L. (2007). Stem Cell Transplantation in Multiple Myeloma. ASH Education Book 2007: 311-316 [Abstract] [Full Text]  
• Harousseau, J.-L., Shaughnessy, J. Jr., Richardson, P. (2004). Multiple Myeloma. ASH Education Book 2004: 237-256 [Abstract] [Full Text]  
• Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E. G., Cornelissen, J. J., Schaafsma, M. R., van Oers, M. H. J., Wijermans, P. W., Fibbe, W. E., Wittebol, S., Schouten, H. C., Kooy, M. v. M., Biesma, D. H., Baars, J. W., Slater, R., Steijaert, M. M. C., Buijt, I., Lokhorst, H. M. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101: 2144-2151 [Abstract] [Full Text]